Calcium gluconate
General
- Type: Electrolyte
- Dosage Forms: injectable solution, tablet, capsule
- Dosage Strenths: injectable solution: 100mg/mL; tablet: 50, 500, 650mg; capsule: 500mg
- Routes of Administration: PO, IV
- Common Trade Names:
Adult Dosing
- Calcium Supplementation
- 19-50 years old: 1000mg/day PO (divided q8-12hr)
- >50 years old: 1200mg/day PO (divided q8-12hr)
- Pregnant or breastfeeding patient: 1000mg/day PO (divided q8-12hr)
- Hypocalcemia
- Mild (Calcium 1-1.2 mmol/L)
- 1-3 g/day PO in divided doses
- 1-2 g IV over 2 hours
- Severe (Calcium < 1 mmol/L)
- without seizure or tetany: 0.5mg/kg/hr IV, may be increased to 2mg/kg/hr
- Hypocalcemic tetany:
- 100-300mg elemental calcium (~3g calcium gluconate) IV over 5-10 min
- Followed by continuous IV infusion at 0.5mg/kg/hr
- Mild (Calcium 1-1.2 mmol/L)
- Calcium channel blocker toxicity: 3g IV (30-60mL of 10% soln)
- Beta blocker toxicity: 3g IV (30-60mL of 10% soln)
- Hyperkalemia: Give 10ml of a 10% solution over 10 mins
- Hydrofluoric acid toxicity:[1]
- 25ml 10% calcium gluconate mixed with 75ml water soluble lubricant applied topically
- In severe cases, can infuse 10ml 10% calcium gluconate mixed in 40mL of D5W through arterial catheter over 4 hours
Pediatric Dosing
- Hypocalcemia
- Children: 200 to 500 mg IV (slow injection)
- Infants: up to 200 mg IV (slow injection
- Seizure due to hypocalcemia: 10% calcium gluconate IV 0.3 mL/kg over 5-10min
Special Populations
- Pregnancy Rating: C
- Lactation risk: Use with caution
- Renal Dosing:
- CrCl less than 25 mL/min, base dosing on serum calcium levels
- ESRD: if on HD, may need dose reduction
- Hepatic Dosing: No adjustment
Contraindications
- Hypersensitivity
- Hypercalcemia
- Ventricular fibrillation
- Digoxin toxicity (known or suspected)
- Neonates receiving ceftriaxone sodium injection
Adverse Reactions
Serious
- Bradycardia, vasodilation, hypotension, MI, cardiac arrest
- Tissue necrosis (due to extravasation)
- Urolithiasis
- Prostate cancer
Common
- Constipation, abdominal bloating, flatulence
- Headache
Pharmacology
- Half-life:
- Metabolism:
- Absorption requires Vitamin D
- Absorption is increased with acidic condition; thus, administer 1-2 hr after meals
- ~45% protein bound (primarily to albumin)
- Excretion: feces as unabsorbed calcium salt (80%), urine (20%)
Mechanism of Action
- Bone mineral component; cofactor in enzymatic reactions, essential for neurotransmission, muscle contraction, and many signal transduction pathways.
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Calcium channel blocker toxicity | 3 g (30-60 mL of 10% solution) IV bolus | Calcium supplementation | IV | Adult |
| Hydrofluoric acid | Topical gel (3.5g powder in 150mL lubricant or 25mL 10% soln in 75mL lubricant) | Minor cutaneous burns (<50 cm2 from <20% solutions) | Topical | Adult |
| Hydrofluoric acid | 5% intradermal injection (max 0.5mL/cm2) | Severe cutaneous burns | Intradermal | Adult |
| Hydrofluoric acid | 10mL of 10% in 40mL NS via Bier block (20min dwell time) | Refractory cutaneous burns | IV regional (Bier block) | Adult |
| Hydrogen fluoride toxicity | 100mg IV (10mL of 10% solution) over 2-3 min | Systemic HF exposure, correct hypocalcemia | IV | Adult |
| Hypermagnesemia | 15-30mL of 10% solution | Antagonize cardiac/respiratory effects of hypermagnesemia (alternative to calcium chloride) | IV | Adult |
| Hypocalcemia | 1g PO Q6hrs | Asymptomatic hypocalcemia | PO | Adult |
| Hypocalcemia | 10mL of 10% solution | Symptomatic hypocalcemia | IV | Adult |
| Seizure (peds) | 0.3mL/kg of 10% solution over 5-10min | Hypocalcemic seizure | IV | Pediatric |
| Tumor lysis syndrome | 50-200 mg | Symptomatic hypocalcemia | IV | Adult |
See Also
References
- ↑ Su M. Hydrofluoric Acid. In: Goldfrank’s Toxicologic Emergencies, 10e. 2016.
